BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature Goldman Sachs hosted an investor meeting with BioMarin Pharmaceutical Inc's (NASDAQ: BMRN ) Alexander Hardy (President and CEO) and Brian Mueller (EVP, CFO). They reiterated financial guidance after reviewing their assumptions around Voxzogo competition post-Ascendis Pharma's better-than-expected Phase 3 achondroplasia data. The analyst notes that management believes a U.S./EU launch by Ascendis Pharma could violate its C-type natriuretic peptide (CNP) patents However, excluding this concern, the company still expects to reach approximately $4 billion in total revenue for fiscal year 2027, driven by growing Voxzogo adoption in the U.S., aided by its broad label without lower age restrictions, which could provide a competitive edge over Ascendis Pharma. The company is targeting an adjusted operating margin of low-to-mid 40% (starting at 40% in
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- BioMarin Pharmaceutical reaffirms long-term outlook [Seeking Alpha]Seeking Alpha
- BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society MeetingPR Newswire
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Scotiabank from $95.00 to $78.00. They now have a "sector perform" rating on the stock.MarketBeat
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Wells Fargo & Company from $115.00 to $90.00. They now have an "overweight" rating on the stock.MarketBeat
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Truist Financial Co. from $118.00 to $90.00. They now have a "buy" rating on the stock.MarketBeat
BMRN
Earnings
- 8/5/24 - Beat
BMRN
Sec Filings
- 9/24/24 - Form 8-K
- 9/17/24 - Form 4
- 9/4/24 - Form 8-K
- BMRN's page on the SEC website